Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027027 · ClinicalTrials.gov registry record · Phase 1
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00027027 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 21 participants.
The verdict
NCT00027027, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without causing severe side effects. All study participants will be assigned to specific group to evaluate different dosages of rhuMAb 2C4. The study is scheduled to run for up to one year depending on how patients respond to the study treatment.
Interventions
- DRUG rhuMAb 2C4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2001-11 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027027
The ClinicalTrials.gov registry entry for NCT00027027 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhuMAb 2C4 is the first listed.
NCT00027027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027027 about?
NCT00027027 is a clinical study titled "Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors". The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without causing severe side effects. All study participants will be assigned to spec...
What is the current status of trial NCT00027027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2001-11. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00027027?
The interventions under investigation include: rhuMAb 2C4 (DRUG).
Who is sponsoring clinical trial NCT00027027?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.